Department of Prosthodontics, Faculty of Dentistry, Aristotle University of Thessaloniki, University Campus, Dentistry Building, GR-54124, Thessaloniki, Greece.
Department of Physiology and Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, University Campus, GR-54006, Thessaloniki, Greece.
Stem Cell Rev Rep. 2020 Dec;16(6):1222-1241. doi: 10.1007/s12015-020-09980-x.
Mesenchymal stem cells (MSCs) have appeared as a promising regenerative cell-based therapeutic, for degenerative conditions, such as OA, while the beneficial results from the application of MSCs have been attributed to the MSCs-derived secretome, which is the sum of cytoprotective factors produced by the MSCs. Aim of this study was to systematically review the literature in order to assess whether stem cell secretome (conditioned medium-CM, exosome-Exos or microvesicles-MV)(CM/Exos/MVs) treatment reduces inflammation and enhances cartilage regeneration in preclinical studies of experimental arthritis.
An extensive electronic search was conducted by 2 independent reviewers by using the PubMed, Cochrane Library, Web of Science, and Scopus database, as well as Google Scholar, in order to identify the studies that met our inclusion criteria until August 2019. Included studies were assessed for quality and Risk of Bias (RoB) using the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines and a modification of Systematic Review Centre for Laboratory animal Experimentation (SYRCLE) RoB tool for animal studies, respectively.
The initial search provided 525 records, with 28 fulfilling the inclusion criteria. The included studies presented great heterogeneity regarding the stem cells used, the preparation of therapeutic agent as well as the animal models used for testing. In addition, most studies presented with an unclear or high risk bias.
In summary, the positive results of CM/Exos/MVs application in preclinical models of experimentally induced OA in terms of resolution of inflammation and cartilage regeneration are highlighted in this review, presenting a promising therapeutic solution for OA.
间充质干细胞（MSCs）作为一种有前途的基于再生细胞的治疗方法，已经出现用于治疗退行性疾病，如 OA，而 MSC 应用的有益结果归因于 MSC 衍生的分泌组，它是 MSC 产生的细胞保护因子的总和。本研究的目的是系统地回顾文献，以评估干细胞分泌组（条件培养基-CM、外泌体-Exos 或微泡-MV）（CM/Exos/MVs）治疗是否能减轻炎症并增强实验性关节炎的软骨再生。
两名独立的审查员通过使用 PubMed、Cochrane 图书馆、Web of Science 和 Scopus 数据库以及 Google Scholar 进行了广泛的电子搜索，以确定符合我们纳入标准的研究，直到 2019 年 8 月。使用动物研究报告体内实验（ARRIVE）指南和系统评价中心实验室动物实验（SYRCLE）风险偏倚工具对纳入的研究进行质量和风险偏倚（RoB）评估。
最初的搜索提供了 525 条记录，其中 28 条符合纳入标准。纳入的研究在使用的干细胞、治疗剂的制备以及用于测试的动物模型方面存在很大的异质性。此外，大多数研究存在不明确或高风险的偏倚。
总之，本综述强调了 CM/Exos/MVs 在实验性诱导的 OA 动物模型中应用在炎症缓解和软骨再生方面的积极结果，为 OA 提供了一种有前途的治疗方法。
